Surgery in mesothelioma-where do we go after MARS?

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 525-529

  Hiddinga, Birgitta I ^a   Van Meerbeeck, Jan P ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Extended pleurectomy decortication; Extrapleural pleuropneumonectomy; Lung sparing procedures; Malignant pleural mesothelioma; Multimodality treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

CANCER PALLIATIVE THERAPY; DECORTICATION; HUMAN; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; REVIEW; SURGICAL MORTALITY; SURVIVAL RATE; THORACOTOMY; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 84876419993     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828353d7     Document Type: Review

References (42)

1. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-1703.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothe-lioma epidemic. Br J Cancer 1999;79:666-672.
3. van Meerbeeck J P, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011;78:92-111.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of peme-trexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
5. van Meerbeeck J P, Gaafar R, Manegold C, et al.; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothe-lioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
6. Maziak DE, Gagliardi A, Haynes AE, Mackay JA, Evans WK; Cancer Care Ontario Program in Evidence-based Care Lung Cancer Disease Site Group. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-169.
7. Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008;33:83-88.
8. Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard M, Ritchie AJ. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005;31:314-320.
9. Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001;20:1117-1121.
10. Rice D, Rusch V, Pass H, et al.; International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform defnitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011;6:1304-1312.
11. Treasure T, Internullo E, Fiorentino F, et al. A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg 2011;12:341-346.
12. Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med 2011;104:69-80.
13. Zahid I, Sharif S, Routledge T, Scarci M. Is pleurectomy and decortica-tion superior to palliative care in the treatment of malignant pleural meso-thelioma? Interact Cardiovasc Thorac Surg 2011;12:812-817.
14. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6, 626.e1.
15. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-743.
16. Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007;12:850-863.
17. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extra-pleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63.
18. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965.
19. Utley M, Fiorentino F, Treasure T. Obtaining an upper estimate of the survival beneft associated with surgery for mesothelioma. Eur J Cardiothorac Surg 2010;38:241-244.
20. Weder W, Stahel RA, Bernhard J, et al.; Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202.
21. Krug LM, Pass HI, Rusch V W, et al. Multicenter phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonec-tomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
22. Van Schil PE, Baas P, Gaafar R, et al.; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-1369.
23. Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol 2009;4:1254-1258.
24. Treasure T, Lang-Lazdunski L, Waller D, et al.; MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.
25. Rusch V W. The Mars trial: resolution of the surgical controversies in mesothelioma? J Thorac Oncol 2009;4:1189-1191.
26. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093-1094; author reply 1094.
27. Reno O. Extrapleural pneumonectomy in malignant pleural mesotheli-oma. Should be limited only to patients enrolled in trials, according to new trial evidence. BMJ 2011;343:d5706 doi: 10.1136/bmj.d5706
28. Wanebo HJ, Martini N, Melamed MR, Hilaris B, Beattie EJ Jr. Pleural mesothelioma. Cancer 1976;38:2481-2488.
29. Branscheid D, Krysa S, Bauer E, Bülzebruck H, Schirren J. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991;5:466-472; discussion 473.
30. Allen KB, Faber L P, Warren WH. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am 1994;4:113-126.
31. Pass H W, Temeck BK, Kranda K, et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduc-tion. Ann Surg Oncol 1997;4:215-222.
32. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-317; discussion 317.
33. Rusch V W, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804.
34. Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decor-tication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007;31:765-770; discussion 770.
35. Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg 2010;37:552-556.
36. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-743.
37. Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer 2012;77:151-155.
38. Rusch V W, Giroux D, Kennedy C, et al.; IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7:1631-1639.
39. Lang-Lazdunski L, Bille A, Belcher E, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2011;6:1746-1752.
40. Treasure T, Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133:1414-1418.
41. Steele JP. Randomised trial of extended pleurectomy and decortication (EPD) with pemetrexed and platinum chemotherapy versus pemetrexed and platinum alone in patients with malignant pleural mesothelioma (̀MARS-2̀). Proc IMIG 2012, Boston 12-14 September 2012, P3.22.
42. Lang-Lazdunski L, Van Meerbeeck J P, Vermassen F, et al. EORTC randomised phase II study of extended pleurectomy/decortication (e-P/D) preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (MPM). Proc IMIG 2012, Boston 12-14 September 2012, P4.14.